Impact of genetic variations on side effects from capecitabine in Egyptian cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate how a specific genetic variation in the CES1 gene affects the toxicity experienced by Egyptian patients undergoing capecitabine-based chemotherapy for colorectal or breast cancer. By focusing on the single nucleotide polymorphism rs2244613, the study seeks to understand the variability in drug response among individuals. Participants will be those already receiving capecitabine as part of their standard treatment, allowing for real-world insights into genetic influences on drug toxicity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy
* Age \> 18 years
* ECOG PS 0-2.

Exclusion Criteria:

* Patients treated with irinotecan
* Lack of physical integrity of the upper gastrointestinal tract
* Patients with malabsorption syndrome
* Patients having inability to take oral medication
* Patients with poor performance status
* Patients with chronic diarrhea as ulcerative colitis or Crohn's disease

Where it's running

• Department of Clinical Oncology, Faculty of Medicine, Menoufia University
  Shibīn al Kawm, Menoufia, Egypt Recruiting

Study contacts

• Study coordinator: Raghad Nassar, Teaching Assistant
• Email: raghad.essam22@pharma.asu.edu.eg
• Phone: 01004446077

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Prospective look at liver metastases imaging and tissue patterns in colorectal and breast cancer

  This observational study tests whether 3D maps of histopathological growth patterns in liver metastases align with imaging features from MRI/CT in patients undergoing liver surgery.

  Recruiting Cancer Research Antwerp · Wilrijk, Antwerp · NCT07781306

• Oral, Fecal and Tumor Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy

  This study tests how the oral, gut, and tumor microbiomes relate to response to first-line immunotherapy in Colombian adults with advanced solid cancers.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07676461

• Precision navigation to boost cancer screening participation in high-risk communities

  This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.

  Recruiting at 3 sites Hunan Cancer Hospital · Huaihua, Hunan and 2 other locations · NCT07676383

• Targeted radiopharmaceuticals for GRPR-positive cancers in adults

  A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.

  Recruiting Phase 1 Alpha-9 Oncology USA Inc. · Melbourne N., Victoria and 1 other locations · NCT07661641

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.